Evaluation of oxidative and nitrosative stress in relapsing remitting multiple sclerosis: Effect of corticosteroid therapy

Folia Neuropathologica

Volumn 51, Issue 1, 2013, Pages 58-64

  Seven, Arzu ^a   Aslan, Mahmure ^b   Incir, Said ^c   Altintaş, Ayşe ^c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Hospitalium Hospital   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

CSF; Methylprednisolone; Multiple sclerosis; Oxidative nitrosative stress

Indexed keywords

3 NITROTYROSINE; METHYLPREDNISOLONE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROMETRY; HUMAN; LIPID PEROXIDATION; MALE; MULTIPLE SCLEROSIS; NITROSATIVE STRESS; NORMOTENSIVE HYDROCEPHALUS; OXIDATIVE STRESS; SPECTROPHOTOMETRY;

EID: 84876277069     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: 10.5114/fn.2013.34197     Document Type: Article

References (31)

1. Adibhatla RM, Hatcher JF. Phospholipase A(2), reactive oxygen species, and lipid peroxidation in CNS pathologies. BMB Rep 2008; 41: 560-567.
2. Beuge JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978; 52: 302-310.
3. Bolanos JP, Heales SJ. Persistent mitochondrial damage by nitric oxide and its derivatives: neuropathological implications. Front Neuroenergetics 2010; 2: 1-5.
4. Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci 2002; 23: 360-366.
5. De Bustos F, Navarro JA, De Andrés C. Cerebrospinal fluid nitrate levels in patients with multiple sclerosis. Eur Neurol 1999; 41: 44-47.
6. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175-1189.
7. Giovannoni G, Miller DH, Losseff NA, Sailer M, Lewellyn-Smith N, Thompson AJ, Thompson EJ. Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis. J Neurol 2001; 248: 487-495.
8. Greco A, Minghetti L, Puopolo M, Cannoni S, Romano S, Pozzilli C, Levi G. Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsing-remitting multiple sclerosis. J Neurol Sci 2004; 224: 23-27.
9. Hunter MIS, Nlemadim BC, Davidson DLW. Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients. Neurochem Res 1985; 10: 1645-1652.
10. Iarlori C, Gambi D, Lugaresi A, Patruno A, Felaco M, Salvatore M, Speranza L, Reale M. Reduction of free radicals in multiple sclerosis: effect of glatiramer acetate (Copaxone). Mult Scler 2008; 14: 739-748.
11. Keles MS, Taysi S, Sen N, Aksoy H, Akçay F. Effect of corticosteroid therapy on serum and CSF malondialdehyde and antioxidant proteins in multiple sclerosis. Can J Neurol Sci 2001; 28: 141-143.
12. Koch M, Mostert J, Arutjunyan AV, Stepanov M, Teelken A, Heersema D, De Keyser J. Plasma lipid peroxidation and progression of disability in multiple sclerosis. Eur J Neurol 2007; 14: 529-533.
13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
14. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911.
15. Mattsson N, Haghighi S, Andersen O, Yao Y, Rosengren L, Blennow K, Praticò D, Zetterberg H. Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. Neurosci Lett 2007; 414: 233-236.
16. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman ChH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, Van Den Noort S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
17. Miller E, Mrowicka M, Saluk-Juszczak J, Ireneusz M. The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis. Neurochem Res 2011; 36: 1012-1016.
18. Miller E, Walczak A, Saluk J, Ponczek MB, Majsterek I. Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis. Clin Biochem 2012; 45: 26-30.
19. Mitosek-Szewczyk K, Gordon-Krajcer W, Walendzik P, Stelmasiak Z. Free radical peroxidation products in cerebrospinal fluid and serum of patients with multiple sclerosis after glucocorticoid therapy. Folia Neuropathol 2010; 48: 116-122.
20. Naidoo R, Knapp ML. Studies of lipid peroxidation products in the cerebrospinal fluid and serum in multiple sclerosis and other conditions. Clin Chem 1992; 38: 2449-2454.
21. Nazliel B, Tǎkiran D, Irkec C, Kutay FZ, Pöǧün S. Serum nitric oxide metabolites in patients with multiple sclerosis. J Clin Neurosci 2002; 9: 530-532.
22. Nessler S, Brück W. Advances in multiple sclerosis research in 2009. J Neurol 2010; 257: 1590-1593.
23. Ortiz GG, Macías-Islas MA, Pacheco-Moisés FP, Cruz-Ramos JA, Sustersik S, Barba EA, Aguayo A. Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Dis Markers 2009; 26: 35-39.
24. Rejdak K, Petzold A, Stelmasiak Z, Giovannoni G. Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Mult Scler 2008; 14: 59-66.
25. Rogovina NI, Khokhlov AP. Metabolism of lipid peroxidation products in multiple sclerosis patients. Zhurnal Nevropatologii i Psikhiatrii Imeni S. S. Korsakova 1980; 80: 696-700.
26. Slater TF. Overview of methods used for detecting lipid peroxidation. Methods Enzymol 1984; 105: 283-293.
27. Su KG, Banker G, Bourdette D, Forte M. Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis. Curr Neurol Neurosci Rep 2009; 9: 411-417.
28. Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 2009; 7: 65-74.
29. Witherick J, Wilkins A, Scolding N, Kemp K. Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment. Autoimmune Dis 2010; 2011: 1-11.
30. Yamashita T, Ando Y, Obayashi K. Changes in nitrite and nitrate levels in cerebrospinal fluid of patients with multiple sclerosis. J Neurol Sci 1997; 153: 32-34.
31. Yuceyar N, Taskiran D, Sagduyu A. Serum and cerebrospinal fluid nitrite and nitrate levels in relapsing-remitting and secondary progressive multiple sclerosis patients. Clin Neurol Neurosurg 2001; 103: 206-211.